NO20055283L - Karbohydrat-derivater av rapamycin - Google Patents

Karbohydrat-derivater av rapamycin

Info

Publication number: NO20055283L
Authority: NO; Norway
Prior art keywords: rapamycin; derivatives; carbohydrate derivatives; profiles; pharmacokinetic
Prior art date: 2003-05-16

Application number

NO20055283A

Other languages

English (en)

Norwegian (no)

Other versions

NO20055283D0 (no

Inventor

Randall W Yatscoff

Robert T Foster

Mark Abel

Roman Szweda

Daniel Trepanier

Original Assignee

Isotechnika Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-16

Filing date

2005-11-10

Publication date

2005-12-16

2005-11-10 Application filed by Isotechnika Inc filed Critical Isotechnika Inc

2005-11-10 Publication of NO20055283D0 publication Critical patent/NO20055283D0/no

2005-12-16 Publication of NO20055283L publication Critical patent/NO20055283L/no

Links

ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 4
229960002930 sirolimus Drugs 0.000 title abstract 4
150000001719 carbohydrate derivatives Chemical class 0.000 title 1
-1 rapamycin carbohydrate derivatives Chemical class 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000002772 monosaccharides Chemical class 0.000 abstract 1
229920001542 oligosaccharide Polymers 0.000 abstract 1
150000002482 oligosaccharides Chemical class 0.000 abstract 1
230000003285 pharmacodynamic effect Effects 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Oncology (AREA)
Crystallography & Structural Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Hematology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Materials For Medical Uses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Prostheses (AREA)

NO20055283A 2003-05-16 2005-11-10 Karbohydrat-derivater av rapamycin NO20055283L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US47136703P	2003-05-16	2003-05-16
US54624004P	2004-02-20	2004-02-20
US56284004P	2004-04-16	2004-04-16
PCT/CA2004/000724 WO2004101583A1 (en)	2003-05-16	2004-05-14	Rapamycin carbohydrate derivatives

Publications (2)

Publication Number	Publication Date
NO20055283D0 NO20055283D0 (no)	2005-11-10
NO20055283L true NO20055283L (no)	2005-12-16

Family

ID=33458770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055283A NO20055283L (no)	2003-05-16	2005-11-10	Karbohydrat-derivater av rapamycin

Country Status (19)

Country	Link
US (3)	US7160867B2 (pl)
EP (2)	EP1644392B1 (pl)
JP (1)	JP2007503452A (pl)
KR (1)	KR20060031603A (pl)
AT (1)	ATE367396T1 (pl)
AU (1)	AU2004238408A1 (pl)
BR (1)	BRPI0411171A (pl)
CA (1)	CA2525907A1 (pl)
DE (1)	DE602004007662T2 (pl)
DK (1)	DK1644392T3 (pl)
ES (1)	ES2286637T3 (pl)
HR (1)	HRP20070383T3 (pl)
MX (1)	MXPA05012376A (pl)
NO (1)	NO20055283L (pl)
NZ (1)	NZ543479A (pl)
PL (1)	PL1644392T3 (pl)
PT (1)	PT1644392E (pl)
TW (1)	TW200511991A (pl)
WO (1)	WO2004101583A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6955661B1 (en)	1999-01-25	2005-10-18	Atrium Medical Corporation	Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US7160867B2 (en) *	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives
US8021331B2 (en)	2003-09-15	2011-09-20	Atrium Medical Corporation	Method of coating a folded medical device
JP2007505932A (ja) *	2003-09-18	2007-03-15	マクサイト，インコーポレイテッド	経強膜送達
US7563780B1 (en) *	2004-06-18	2009-07-21	Advanced Cardiovascular Systems, Inc.	Heparin prodrugs and drug delivery stents formed therefrom
US9000040B2 (en)	2004-09-28	2015-04-07	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
WO2006086750A1 (en) *	2005-02-09	2006-08-17	Macusight, Inc.	Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) *	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
GB0504994D0 (en)	2005-03-11	2005-04-20	Biotica Tech Ltd	Novel compounds
WO2006119018A2 (en) *	2005-04-29	2006-11-09	Atrium Medical Corporation	Drug delivery coating for use with a medical device and methods of treating vascular injury
EP2275103B1 (en)	2005-11-21	2014-04-23	Novartis AG	mTOR inhibitors in the treatment of endocrine tumors
US8492400B2 (en)	2006-02-09	2013-07-23	Santen Pharmaceutical Co., Ltd.	Stable formulations, and methods of their preparation and use
CN101443004B (zh) *	2006-03-23	2013-03-06	参天制药株式会社	用于与血管通透性有关的疾病或病症的制剂
GB0609963D0 (en) *	2006-05-19	2006-06-28	Biotica Tech Ltd	Novel compounds
US20080265343A1 (en) *	2007-04-26	2008-10-30	International Business Machines Corporation	Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20090253733A1 (en) *	2008-04-02	2009-10-08	Biointeractions, Ltd.	Rapamycin carbonate esters
CN101676291B (zh) *	2008-09-18	2012-05-09	上海海和药物研究开发有限公司	一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
PT2365802T (pt)	2008-11-11	2017-11-14	Univ Texas	Microcápsulas de rapamicina e utilização para o tratamento de cancro
US8653043B2 (en)	2009-01-07	2014-02-18	Wisconsin Alumni Research Foundation	Enhanced neoglycosides through neoglycosylation and methods of use thereof
EP2470179B1 (en)	2009-08-26	2017-11-29	Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.	Sustained release delivery systems for the prevention and treatment of head and neck cancers
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
EP2694520A1 (en) *	2011-04-01	2014-02-12	Sandoz AG	Regioselective acylation of rapamycin at the c-42 position
EP2589383A1 (en)	2011-11-06	2013-05-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin	FKBP subtype-specific rapamycin analogue for use in treatment of diseases
NZ631340A (en)	2012-03-23	2016-11-25	Univ Queensland	Immunomodulatory agent and uses therefor
US9408884B2 (en)	2012-06-08	2016-08-09	Biotronik Ag	Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
US10751450B2 (en)	2012-06-08	2020-08-25	Biotronik Ag	Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
WO2014160328A1 (en)	2013-03-13	2014-10-02	The Board Of Regents Of The University Of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
WO2014184734A1 (en)	2013-05-14	2014-11-20	Novartis Ag	Markers associated with mtor inhibition
CA2928568A1 (en)	2013-07-26	2015-01-29	Update Pharma Inc.	Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2015044854A1 (en)	2013-09-24	2015-04-02	Novartis Ag	Markers associated with mtor inhibition
AU2014373683B2 (en)	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
JP6770008B2 (ja)	2016-05-10	2020-10-14	浙江海正薬業股▲ふん▼有限公司ＺｈｅｊｉａｎｇＨｉｓｕｎＰｈａｒｍａｃｅｕｔｉｃａｌＣＯ．，ＬＴＤ．	水溶性ラパマイシン誘導体
EP3848065B1 (en)	2017-05-15	2023-07-26	C. R. Bard, Inc.	Medical device with drug-eluting coating and intermediate layer
CA3098698A1 (en)	2018-05-01	2019-11-07	Revolution Medicines, Inc.	C26-linked rapamycin analogs as mtor inhibitors
CN118978535A (zh) *	2018-05-01	2024-11-19	锐新医药公司	作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
JP7262581B2 (ja)	2018-11-14	2023-04-21	ルトニックス，インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
EP4272825A3 (en)	2019-01-22	2023-12-06	Aeovian Pharmaceuticals, Inc.	Mtorc modulators and uses thereof
JP7487228B2 (ja)	2019-04-08	2024-05-20	バード・ペリフェラル・バスキュラー・インコーポレーテッド	改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
JP2025522296A (ja)	2022-05-25	2025-07-15	レヴォリューション・メディスンズ，インコーポレイテッド	ｍＴＯＲ阻害剤によりがんを処置する方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3226179A (en) *	1962-10-01	1965-12-28	Huyck Corp	Papermaker's felt, woven fabrics and fibers of wool modified with an aldehyde - 4,4 - bis(4 - hydroxy phenyl) pentanoic acid reaction product and the production thereof
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US4316685A (en) *	1980-02-29	1982-02-23	Black & Decker Inc.	Plunge type router
US4316885A (en)	1980-08-25	1982-02-23	Ayerst, Mckenna And Harrison, Inc.	Acyl derivatives of rapamycin
US4650803A (en)	1985-12-06	1987-03-17	University Of Kansas	Prodrugs of rapamycin
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5023263A (en)	1990-08-09	1991-06-11	American Home Products Corporation	42-oxorapamycin
US5023262A (en)	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
US5378696A (en)	1990-09-19	1995-01-03	American Home Products Corporation	Rapamycin esters
PT98990A (pt)	1990-09-19	1992-08-31	American Home Prod	Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5358944A (en)	1990-09-19	1994-10-25	American Home Products Corporation	Rapamycin esters for treating transplantation rejection
US5432183A (en)	1991-05-31	1995-07-11	Pfizer Inc.	Use of rapamycin prodrugs as immunosuppressant agents
US5457111A (en)	1991-09-05	1995-10-10	Abbott Laboratories	Macrocyclic immunomodulators
US5162333A (en)	1991-09-11	1992-11-10	American Home Products Corporation	Aminodiesters of rapamycin
ATE205496T1 (de)	1992-03-02	2001-09-15	Pfizer	Desosamino-derivate von makroliden als immunosuppressive und antifungale mittel
DE69314947T2 (de)	1992-03-02	1998-03-05	Pfizer Inc., New York, N.Y.	2-aminozuckermakrolid-derivate
CA2132457C (en)	1992-03-02	1998-06-16	Kevin Koch	Fluorosugar derivatives of macrolides
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5434260A (en)	1992-10-13	1995-07-18	American Home Products Corporation	Carbamates of rapamycin
DE4236237A1 (de)	1992-10-27	1994-04-28	Behringwerke Ag	Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5262423A (en)	1992-10-29	1993-11-16	American Home Products Corporation	Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en)	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en)	1992-11-19	1993-11-09	American Home Products Corporation	Rapamycin carbonate esters as immuno-suppressant agents
USRE37421E1 (en)	1993-07-16	2001-10-23	Smithkline Beecham Corporation	Rapamycin derivatives
WO1995014023A1 (en)	1993-11-19	1995-05-26	Abbott Laboratories	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en)	1993-11-19	1996-06-18	Abbott Laboratories	Macrolide immunomodulators
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5563145A (en)	1994-12-07	1996-10-08	American Home Products Corporation	Rapamycin 42-oximes and hydroxylamines
AU692255B2 (en)	1995-04-24	1998-06-04	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Self-emulsifiable formulation producing an oil-in-water emulsion
US6187757B1 (en)	1995-06-07	2001-02-13	Ariad Pharmaceuticals, Inc.	Regulation of biological events using novel compounds
CZ292233B6 (cs)	1995-06-09	2003-08-13	Novartis Ag	Deriváty rapamycinu a jejich použití jako léčiv
FR2736550B1 (fr)	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
EP0795334B1 (de)	1996-03-12	2006-02-01	Sanofi-Aventis Deutschland GmbH	Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
US6103884A (en)	1996-03-27	2000-08-15	The University Of Michigan	Glycosylated analogs of fusidic acid
WO1998004279A1 (en)	1996-07-30	1998-02-05	Novartis Ag	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
US6884429B2 (en) *	1997-09-05	2005-04-26	Isotechnika International Inc.	Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6342507B1 (en)	1997-09-05	2002-01-29	Isotechnika, Inc.	Deuterated rapamycin compounds, method and uses thereof
US6153252A (en)	1998-06-30	2000-11-28	Ethicon, Inc.	Process for coating stents
US6015809A (en)	1998-08-17	2000-01-18	American Home Products Corporation	Photocyclized rapamycin
DE60041255D1 (de) *	1999-04-28	2009-02-12	Eidgenoess Tech Hochschule	Polyionische beschichtungen für analytische und sensor-vorrichtungen
US6277983B1 (en)	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
US6670355B2 (en)	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
US6399626B1 (en)	2000-10-02	2002-06-04	Wyeth	Hydroxyesters of 7-desmethylrapamycin
US6641611B2 (en) *	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
US7160867B2 (en) *	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives

2004
- 2004-05-13 US US10/845,747 patent/US7160867B2/en not_active Expired - Fee Related
- 2004-05-14 KR KR1020057021769A patent/KR20060031603A/ko not_active Ceased
- 2004-05-14 PT PT04732898T patent/PT1644392E/pt unknown
- 2004-05-14 DE DE602004007662T patent/DE602004007662T2/de not_active Expired - Fee Related
- 2004-05-14 JP JP2006529489A patent/JP2007503452A/ja not_active Withdrawn
- 2004-05-14 PL PL04732898T patent/PL1644392T3/pl unknown
- 2004-05-14 ES ES04732898T patent/ES2286637T3/es not_active Expired - Lifetime
- 2004-05-14 CA CA002525907A patent/CA2525907A1/en not_active Abandoned
- 2004-05-14 EP EP04732898A patent/EP1644392B1/en not_active Expired - Lifetime
- 2004-05-14 BR BRPI0411171-0A patent/BRPI0411171A/pt not_active IP Right Cessation
- 2004-05-14 NZ NZ543479A patent/NZ543479A/en unknown
- 2004-05-14 MX MXPA05012376A patent/MXPA05012376A/es active IP Right Grant
- 2004-05-14 WO PCT/CA2004/000724 patent/WO2004101583A1/en not_active Ceased
- 2004-05-14 DK DK04732898T patent/DK1644392T3/da active
- 2004-05-14 EP EP07003243A patent/EP1785430A1/en not_active Withdrawn
- 2004-05-14 TW TW093113648A patent/TW200511991A/zh unknown
- 2004-05-14 AU AU2004238408A patent/AU2004238408A1/en not_active Abandoned
- 2004-05-14 AT AT04732898T patent/ATE367396T1/de not_active IP Right Cessation
- 2004-05-14 HR HR20070383T patent/HRP20070383T3/xx unknown
2005
- 2005-09-15 US US11/229,007 patent/US20060079466A1/en not_active Abandoned
- 2005-11-10 NO NO20055283A patent/NO20055283L/no not_active Application Discontinuation
2006
- 2006-11-09 US US11/595,397 patent/US20070099848A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL1644392T3 (pl)	2007-12-31
DE602004007662D1 (de)	2007-08-30
HRP20070383T3 (hr)	2007-10-31
US20070099848A1 (en)	2007-05-03
JP2007503452A (ja)	2007-02-22
EP1644392A1 (en)	2006-04-12
US7160867B2 (en)	2007-01-09
KR20060031603A (ko)	2006-04-12
MXPA05012376A (es)	2006-05-25
AU2004238408A1 (en)	2004-11-25
ES2286637T3 (es)	2007-12-01
DE602004007662T2 (de)	2007-11-22
EP1785430A1 (en)	2007-05-16
BRPI0411171A (pt)	2006-07-18
US20040235762A1 (en)	2004-11-25
CA2525907A1 (en)	2004-11-25
TW200511991A (en)	2005-04-01
NZ543479A (en)	2008-03-28
PT1644392E (pt)	2007-08-03
US20060079466A1 (en)	2006-04-13
DK1644392T3 (da)	2007-11-12
ATE367396T1 (de)	2007-08-15
EP1644392B1 (en)	2007-07-18
WO2004101583A1 (en)	2004-11-25
NO20055283D0 (no)	2005-11-10

Legal Events

Date	Code	Title	Description
2010-12-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20055283D0 (no)	2005-11-10	Karbohydrat-derivater av rapamycin
IL189187A (en)	2013-04-30	Polymeric couplings of a252-k and their history, their pharmaceutical preparations and their uses
PL374523A1 (pl)	2005-10-31	Koniugaty pochodna kalicheamycyny-nośnik
MX337751B (es)	2016-03-17	Sacaridos modificados.
DK1592699T3 (da)	2007-05-07	Avermectin og avermectin-monosaccharidderivater substitueret i 4"- eller 4' -positionen, hvilke forbindelser har pesticidegenskaber
WO2006104826A3 (en)	2007-03-01	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
FR2882054B1 (fr)	2007-04-13	Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
DK1594878T3 (da)	2008-10-06	Avermectin-monosaccharidderivater med pesticidegenskaber
DE602005015835D1 (de)	2009-09-17	An der 4"- bzw. 4'-stellung substituiertes avermectin und avermectin-monosaccharid
WO2007075972A3 (en)	2008-12-04	Chlorite formulations, and methods of preparation and use thereof
DE69813496D1 (de)	2003-05-22	Zyklodextrin-Zusammensetzung enthaltend ein Avermectin- oder ein Milbemycin-Derivat
MA29016B1 (fr)	2007-11-01	Derives de pyridine, leur preparation, leur application en therapeutique
EP1845099A4 (en)	2010-10-06	ARTEMISIN- (QINGHAOSU-) DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF
DK1592700T3 (da)	2008-08-04	Avermectin-derivater og Avermectin-monosaccharidderivater der er substitueret i 4'' - eller 4' - stillingen, og som har pesticidegenskaber
DK1079840T3 (da)	2002-11-04	Synergistisk præparat af inulin og et anticancerlægemiddel til anvendelse til behandling af cancer
FR2888748B1 (fr)	2007-10-12	Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
WO2004026319A3 (en)	2004-09-02	Pharmaceutical compositions increasing camp useful for the treatment of cancers
FR2896246B1 (fr)	2008-08-15	Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
CY1110787T1 (el)	2015-06-10	Νεα μορφινικα παραγωγα
ATE370157T1 (de)	2007-09-15	Avermectin-b1-monosaccharidderivative
FR2887249B1 (fr)	2007-09-28	Compose d-glucopyranose 1-[3,5-bis(1,1-dimenthylethyl)-4- hydroxybenzoate] et ses derives, leur preparation et leurs utilisations
BRPI0410638A (pt)	2006-06-13	derivados de azitromicina
WO2005116041A3 (en)	2006-08-24	New aminoglycoside compounds and derivatives thereof
FR2889847B1 (fr)	2007-10-05	Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
FR2893615B1 (fr)	2008-03-07	Derives de 3-acylindole, leur preparation et leur application en therapeutique